ARTICLE | Product Development
Is it time for Biogen to re-diversify?
Sandrock’s departure creates opportunity for his successor to reconsider neurology focus
November 20, 2021 12:56 AM UTC
Biogen’s next head of R&D faces a big decision: maintain the biotech’s decade-long focus on neurology in the hope its current programs pan out, or diversify the pipeline into adjacent therapeutic areas that lower Biogen’s exposure to biology risk.
Since 2010, Biogen Inc. (NASDAQ:BIIB) has been increasingly narrowing its focus to neurology, a disease area deep with unmet medical needs, but rife with biological complexity...